Everolimus

Generic Name
Everolimus
Brand Names
Afinitor, Votubia, Zortress
Drug Type
Small Molecule
Chemical Formula
C53H83NO14
CAS Number
159351-69-6
Unique Ingredient Identifier
9HW64Q8G6G
Background

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions
Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
Associated Therapies
-

RESTOR: PK/PD mTORi Inhibition in Older Adults

Early Phase 1
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-10-26
Last Posted Date
2024-10-26
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
194
Registration Number
NCT06658093
Locations
🇺🇸

The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients

First Posted Date
2024-09-05
Last Posted Date
2024-09-05
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
80
Registration Number
NCT06584773
Locations
🇧🇷

Renal Transplantation Service, Sao Paulo, Brazil

Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

First Posted Date
2024-08-19
Last Posted Date
2024-08-19
Lead Sponsor
Fudan University
Target Recruit Count
260
Registration Number
NCT06561022
Locations
🇨🇳

270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

First Posted Date
2024-05-24
Last Posted Date
2024-12-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT06428396
Locations
🇨🇱

Centro de Investigación del Maule ( Site 4106), Talca, Maule, Chile

🇺🇸

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0011), Marietta, Georgia, United States

🇺🇸

CHRISTUS Highland ( Site 0005), Shreveport, Louisiana, United States

and more 8 locations

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

First Posted Date
2024-04-24
Last Posted Date
2024-12-20
Lead Sponsor
MedSIR
Target Recruit Count
240
Registration Number
NCT06382948
Locations
🇪🇸

Hospital Universitario Doce de Octubre, Madrid, Spain

🇪🇸

Hospital Arnau de Vilanova de Valencia, Valencia, Spain

🇬🇧

Barts Health NHS Trust, London, United Kingdom

and more 1 locations

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-03-08
Last Posted Date
2024-03-08
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT06301386
Locations
🇨🇳

Anyang Tumor Hospital, Anyang, Henan, China

🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

First Posted Date
2024-02-28
Last Posted Date
2024-11-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
340
Registration Number
NCT06280950
Locations
🇺🇸

Mayo Clinic Hospital Arizona (Site #: 71144), Phoenix, Arizona, United States

🇺🇸

University of California, San Francisco (Site #: 71108), San Francisco, California, United States

🇺🇸

Northwestern University (Site #: 71110), Chicago, Illinois, United States

and more 5 locations

Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2023-11-13
Last Posted Date
2024-06-20
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
28
Registration Number
NCT06126588
Locations
🇫🇷

CHRU of Nancy, Vandœuvre-lès-Nancy, Grand Est, France

🇫🇷

Nancy Hospital, Vandœuvre-lès-Nancy, France

© Copyright 2024. All Rights Reserved by MedPath